Aptevo Therapeutics Inc. (APVO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Aptevo Therapeutics reported revenue of $0. Net income was -$26.0M, or -$87.27 per diluted share. Operating activities generated -$25.6M of cash, leaving -$25.6M of free cash flow. At fiscal year end, Aptevo Therapeutics held $27.2M in total assets against $9.8M in total liabilities, including $21.6M of cash and equivalents.
Open the full interactive Aptevo Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Aptevo Therapeutics Key Stats
| Share Price | $1.73 |
|---|---|
| Market Cap | $2.1M |
| 52-Week Range | $1.71 – $29.34 |
| Shares Outstanding | 1.2 million (basic, 2026 Q2) |
Aptevo Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $4.3M | $12.3M | $3.1M | $0 | $0 | $0 |
| Operating Income | -$27.5M | -$21.4M | -$28.6M | -$28.9M | -$24.6M | -$26.3M |
| Pre-Tax Income | -$30.9M | -$29.4M | $7.0M | -$18.6M | -$24.1M | -$26.0M |
| Income Tax | -$13.2M | -$951,000 | -$1.0M | -$1.2M | — | $0 |
| Net Income | -$17.8M | -$28.5M | $8.0M | -$17.4M | -$24.1M | -$26.0M |
| Diluted EPS | -$3065198.40 | -$3557505.60 | $920145.60 | -$832233.60 | -$31456.80 | -$87.27 |
Aptevo Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.5M | -$5.8M | -$6.7M | -$6.4M |
| Diluted EPS | -$40.14 | -$18.40 | -$6.41 | -$5.31 |
Aptevo Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $40.0M | $45.0M | $22.6M | $16.9M | $8.7M | $21.6M |
| Current Assets | $47.3M | $52.6M | $27.4M | $19.1M | $10.7M | $23.1M |
| Total Assets | $53.5M | $56.6M | $34.2M | $24.8M | $15.6M | $27.2M |
| Current Liabilities | $14.5M | $34.8M | $8.7M | $7.2M | $6.2M | $6.0M |
| Total Long-Term Debt | $28.2M | $16.0M | $3.5M | — | — | — |
| Total Liabilities | $37.0M | $55.4M | $16.2M | $12.6M | $10.8M | $9.8M |
| Shareholders' Equity | $16.6M | $1.2M | $18.0M | $12.2M | $4.8M | $17.4M |
Aptevo Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$29.3M | -$21.7M | -$21.0M | -$11.7M | -$23.8M | -$25.6M |
| Cash From Investing | $28.0M | -$713,000 | -$29,000 | — | $0 | $0 |
| Cash From Financing | $23.9M | $26.2M | -$2.6M | $6.0M | $15.6M | $38.5M |
| Free Cash Flow | -$29.4M | -$22.4M | -$21.1M | -$11.8M | -$23.8M | -$25.6M |
Figures from Aptevo Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aptevo Therapeutics financials page for every line item.
Aptevo Therapeutics Company Profile
| Ticker | APVO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Seattle, Washington |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001671584 |
Frequently Asked Questions
What was Aptevo Therapeutics' revenue in fiscal 2025?
Aptevo Therapeutics (APVO) reported revenue of $0 for fiscal 2025.
What is Aptevo Therapeutics' annual revenue history?
Aptevo Therapeutics' annual revenue by fiscal year: 2020: $4.3M; 2021: $12.3M; 2022: $3.1M; 2023: $0; 2024: $0; 2025: $0.
What was Aptevo Therapeutics' net income in fiscal 2025?
Aptevo Therapeutics reported net income of -$26.0M for fiscal 2025.
What was Aptevo Therapeutics' earnings per share (EPS) in fiscal 2025?
Aptevo Therapeutics' diluted EPS was -$87.27 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Aptevo Therapeutics generate in fiscal 2025?
Aptevo Therapeutics generated -$25.6M of free cash flow in fiscal 2025.
What was Aptevo Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Aptevo Therapeutics reported revenue of $0.
How many shares of Aptevo Therapeutics are outstanding?
Aptevo Therapeutics reported a weighted average of 1.2 million basic shares outstanding in 2026 Q2.
What is Aptevo Therapeutics' market cap?
Based on its latest closing price, Aptevo Therapeutics (APVO) has a market capitalization of about $2.1M.
When does Aptevo Therapeutics' fiscal year end?
Aptevo Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Aptevo Therapeutics headquartered?
Aptevo Therapeutics lists its business address in Seattle, Washington in its SEC filings.